ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

3:00PM-4:30PM: Abstract Number: 2198

How Did a Mandatory Switching Policy for Biosimilars in Canada Impact Uptake and Spending?

Abstracts: Health Services Research

3:00PM-4:30PM: Abstract Number: 2211

Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis

Abstracts: Pediatric Rheumatology – Clinical II: JIA

3:00PM-4:00PM: Abstract Number: 2189

Impact of a Fatigue and Energy Management Program for Persons with Systemic Sclerosis (FAME-iSS): A Pilot Study

Abstracts: Cognition and Behavior in RA and Systemic Sclerosis

3:00PM-4:30PM: Abstract Number: 2201

Increased Economic Burden of Uveitis Among Patients with Psoriasis and Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2022

Abstracts: Health Services Research

3:00PM-4:30PM: Abstract Number: 2204

Interosseous Tendon Inflammation in the Hands: A Novel Feature of Developing Rheumatoid Arthritis? Results from a Large MRI Study in Clinically Suspect Arthralgia

Abstracts: Imaging of Rheumatic Diseases

3:00PM-4:30PM: Abstract Number: 2193

Invasive Fungal Diseases in Patients with Autoimmune Diseases: Prospective Data from a Nationwide French Registry

Abstracts: Epidemiology and Public Health II: COVID, Infection and Pregnancy Outcomes

3:00PM-4:30PM: Abstract Number: 2194

Is Vaccination Against Covid-19 Associated with Autoimmune Rheumatic Disease Flare? Self-controlled Case Series Analysis Using Data from the Clinical Practice Research Datalink (Aurum)

Abstracts: Epidemiology and Public Health II: COVID, Infection and Pregnancy Outcomes

3:00PM-4:30PM: Abstract Number: 2216

JAK Inhibitors and Risk of Cancer

Abstracts: RA – Treatment III: Comorbidities and Consequences

3:00PM-4:30PM: Abstract Number: 2212

Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients with Polyarticular or Systemic Juvenile Idiopathic Arthritis – an Extension Study of 2 Phase 1b Clinical Trials

Abstracts: Pediatric Rheumatology – Clinical II: JIA

3:00PM-4:30PM: Abstract Number: 2191

Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea

Abstracts: Epidemiology and Public Health II: COVID, Infection and Pregnancy Outcomes

3:00PM-4:30PM: Abstract Number: 2222

Lupus Clinical Flares in Patients with Gut Pathobiont Blooms Share a Novel Peripheral Blood Transcriptomic Immune Activation Profile

Abstracts: SLE – Diagnosis, Manifestations, and Outcomes III: Genetic Factors

3:00PM-4:00PM: Abstract Number: 2182

mRNA Vaccine Against Fibroblast Activation Protein Ameliorates Murine Models of Inflammatory Arthritis

Abstracts: RA – Animal Models

3:00PM-4:00PM: Abstract Number: 2183

mTORC2 Contributes to Murine Systemic Autoimmunity

Abstracts: T Cell Biology and Targets in Autoimmune and Inflammatory Disease

3:00PM-4:30PM: Abstract Number: 2213

Multi-omic Analysis of Macrophage Activation Syndrome Associated with sJIA Reveals a Potential Role of Type I Interferons in the Expansion of Cycling T Cells

Abstracts: Pediatric Rheumatology – Clinical II: JIA

3:00PM-4:30PM: Abstract Number: 2205

Non-Invasive in Vivo Metabolic Profiling of Inflammation in Joints and Entheses by Optoacoustic Imaging

Abstracts: Imaging of Rheumatic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].